• Explore /
  • Poster
  • / Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL).

Phase II study of Hyper-CVAD with pegylated liposomal doxorubicin alternating with methotrexate and cytarabine (HCVIDD/MA) in patients with newly diagnosed T- and NK-cell lymphoma (T/NKCL).

Abstract Poster

Authors

Dai Chihara

Dai Chihara

The University of Texas MD Anderson Cancer Center, Houston, TX

Dai Chihara , Barbara Pro , Sanam Loghavi , Roberto N. Miranda , L Jeffrey Medeiros , Michelle A. Fanale , Frederick B. Hagemeister , Luis Fayad , Jorge Enrique Romaguera , Felipe Samaniego , Sattva Swarup Neelapu , Anas Younes , Nathan Hale Fowler , Maria Alma Rodriguez , Michael Wang , Larry W. Kwak , Peter McLaughlin , Nam H. Dang , Yasuhiro Oki

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT00290433

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8538)

DOI

10.1200/jco.2015.33.15_suppl.8538

Abstract #

8538

Poster Bd #

355

Abstract Disclosures

Similar Posters

First Author: Kana Miyazaki

First Author: Nicholas James Short

First Author: Nicholas James Short

First Author: Qinglian Tang